Leap Therapeutics Inc (LPTX)

NASDAQ
Currency in USD
Disclaimer
1.3800
-0.0200
(-1.43%)
Closed
1.4100
+0.0300
(+2.1739%)
After Hours
Real-time Data
Day's Range
1.3500
1.4500
52 wk Range
1.2700
10.2000
Volume
120,096
Prev. Close
1.4
Open
1.45
Day's Range
1.35-1.45
52 wk Range
1.27-10.2
Volume
120,096
Average Vol. (3m)
244,819
1-Year Change
-84.62%
Shares Outstanding
25,565,414
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
18.1000
Upside +1,211.5942%

People Also Watch

0.689
DXYN
+4.24%
5.22
INGN
-2.61%
2.520
SLDB
+1.20%
1.960
VERO
-1.51%
How do you feel today about LPTX?
Vote to see community's results!
or

Leap Therapeutics Inc Company Profile

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Income Statement